Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.
Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) is a dynamic clinical-phase biotechnology company that leverages the power of artificial intelligence and machine learning to advance medical research and improve human health. The company's proprietary platform, bfLEAP™, addresses the challenges of scalability and flexibility in data analysis, offering researchers and clinicians a more precise, multi-dimensional understanding of complex biological data.
Bullfrog AI's core business involves utilizing its AI-driven platform to enhance drug development for both internal projects and collaborations with external partners. The company stands at the forefront of AI-driven drug development, using its technology to create and analyze networks of biological, clinical, and real-world data. This innovation spans from early discovery stages to late-stage clinical trials, aiming to streamline data analytics in therapeutic development, thereby reducing failure rates and development costs.
One of the company's recent significant achievements includes a collaboration with the Lieber Institute for Brain Development (LIBD). This partnership successfully stratified brain expression data from over 2,800 brain samples, offering novel insights into psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Through advanced graph analytics and causal AI, this collaboration identified potential molecular subtypes, biomarkers, and drug targets for these conditions.
Financially, Bullfrog AI recently conducted a public offering of 1,507,139 shares of common stock, priced at $3.782 per share, raising approximately $5.7 million before underwriting discounts and offering expenses. WallachBeth Capital LLC acted as the sole book-running manager for this offering, which is expected to close on February 5, 2024, subject to customary closing conditions.
For more information:
- Website: bullfrogai.com
- LinkedIn: Bullfrog AI on LinkedIn
- Investor Contact: Dave Gentry, RedChip Companies, Inc., BFRG@redchip.com, 800-733-2447
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) announced the filing of its Form 10-K with the SEC for the year ending December 31, 2022. This filing, essential for compliance, was initially delayed due to the complexities surrounding its first-time submission, which led to a notice from Nasdaq regarding non-compliance with listing requirements. Following this completed filing, the company has restored its compliance. CEO Vin Singh expressed confidence in avoiding future delays. BullFrog AI focuses on precision medicine through machine learning, collaborating with institutions like Johns Hopkins University to enhance drug development using their proprietary bfLEAP™ platform.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced a strategic partnership with the Sage Group to advance its Phase 2 ready oncology asset targeting glioblastoma, a deadly brain cancer, along with a preclinical prodrug asset. The partnership will leverage Sage Group's clinical and regulatory expertise to identify joint venture opportunities for global clinical development.
The glioblastoma treatment market is projected to exceed $10 billion by 2030, growing from $5.1 billion in 2020, highlighting significant market potential. BullFrog AI has exclusive licenses from Johns Hopkins University for innovative formulations of mebendazole, which have undergone clinical trials, aiming to provide new treatment options for patients.
BullFrog AI Holdings (Nasdaq: BFRG) announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole, signed on October 13, 2022. This world-wide, royalty-bearing license allows BullFrog to commercialize N-substituted prodrugs that improve solubility and bioavailability compared to the original compound. The prodrugs target oncology treatments, notably glioblastoma, leveraging BullFrog's AI technology to enhance drug development efficiency. Vin Singh, the CEO, emphasized the potential of this asset in their oncology pipeline. BullFrog AI is committed to advancing precision medicine through machine learning in drug development, aiming to reduce costs and improve patient outcomes.
RedChip Companies will feature interviews with BullFrog AI (NASDAQ:BFRG) and Alarum Technologies Ltd. (NASDAQ:ALAR) on The RedChip Money Report this Saturday, April 15, at 7 p.m. ET. The program will be broadcast on Bloomberg TV, which reaches approximately 73 million homes in the U.S.
View the interviews online at:
BullFrog AI is focused on precision medicine using its proprietary bfLEAP™ AI platform to enhance drug development and patient therapy matching. Alarum Technologies provides internet access solutions, including privacy and cybersecurity for enterprises and consumers.
FAQ
What is the current stock price of Bullfrog AI Holdings (BFRG)?
What is the market cap of Bullfrog AI Holdings (BFRG)?
What does Bullfrog AI Holdings, Inc. do?
What is bfLEAP?
What are Bullfrog AI's recent achievements?
How does Bullfrog AI's technology benefit drug development?
What financial activities has Bullfrog AI recently conducted?
Who managed Bullfrog AI's recent public offering?
How does Bullfrog AI collaborate with other institutions?
What is the focus of Bullfrog AI's collaboration with the Lieber Institute for Brain Development?
Where can I find more information about Bullfrog AI?
Who is the investor contact for Bullfrog AI?
